Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Influenza

In brief

The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA formulations and 2 dose levels in unadjuvanted rHA formulations.

Key facts

Study ID

NCT01147068

Run by

Protein Sciences Corporation

People needed

392

Starts

2010-06-01

Expected to finish

2011-10-01

Last updated by the study team

2012-11-26

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female aged 18-49 years.
• Give written informed consent to participate.
• Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory evaluation
• Females should fulfill one of the following criteria:
• At least one year post-menopausal;
• Surgically sterile;
• Will use oral, implantable, transdermal or injectable contraceptives for 30 days prior to first vaccination and until 28 days after the booster vaccination; or
• Willing to use another reliable form of contraception approved by the Investigator (e.g., intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual partner) for 30 days prior to first vaccination and until 28 days after the booster vaccination.
• Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of first and booster vaccinations
• Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.

You may not qualify if…

• Persons under 18 years old or 50 years or older
• Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease
• Persons taking medications or treatments that may adversely affect the immune system
• Persons with known allergy to eggs or other vaccine or adjuvant components
• Person currently pregnant, nursing mothers or planning a pregnancy within one month of vaccination
• Persons who have had a prior serious reaction to any influenza vaccine
• Persons with a known history of Guillain-Barré Syndrome
• Persons with a history of anaphylactic-type reaction to injected vaccines
• Persons with a history of drug or chemical abuse in the year preceding the study
• Persons who previously received an H5N1 influenza vaccine or who plan to receive an H5N1 influenza vaccine while participating in the study
• Persons who received a seasonal influenza vaccine six months prior to enrollment (may delay enrollment)
• Persons who received any other vaccine within one week prior to enrollment (may delay enrollment)
• Persons who have had a respiratory illness or illness with fever within three days of study enrollment (may delay enrollment)
• Persons currently participating in another research study involving any study medications (investigational drugs or vaccines).

Where it is running

• Vince and Associates Clinical Research — Overland Park, Kansas, United States
• Meridian Clinical Research — Omaha, Nebraska, United States
• University of Rochester — Rochester, New York, United States
• Benchmark Research — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.